X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. RXRX

Go back to X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights

X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 15c

November 7, 2019 7:06 AM EST

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q3 EPS of ($1.22), $0.15 worse than the analyst estimate of ($1.07).

Third Quarter 2019 Financial Highlights

Cash Position: As of September 30, 2019, cash, cash equivalents and restricted cash were $77.0 million, as compared to $95.6 million as of June 30, 2019. This decrease reflected cash used to fund operating activities during the third quarter and included a $6.5 million cash payment for the settlement of X4\'s loans with Österreichische Forschungsförderungsgesellschaft mbH (FFG). This repayment was part of the debt refinancing executed with Hercules in June 2019, under which X4 has a remaining $5 million in borrowing... More